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Abstract
The effects of gastrin (G17) on the growth and migra-
tion factors of four humanmelanoma cell lines (HT-144,
C32, G-361, and SKMEL-28) were investigated. The
expression patterns of cholecystokinin (CCK)A, CCKB,
and CCKC gastrin receptors were investigated in these
cells and in seven clinical samples by means of reverse
transcription polymerase chain reaction. Melanoma
cells appear to express mRNA for CCKC receptors, but
not for CCKA or CCKB receptors. Although gastrin does
not significantly modify the growth characteristics of
the cell lines under study, it significantly modifies their
cell migration characteristics. These modifications
occur at adhesion level by modifying the expression
levels of Av and B3 integrins, at motility level by modi-
fying the organization of the actin cytoskeleton, and at
invasion level by modifying the expression levels of
matrix metalloproteinase 14. We recently demonstrated
the presence of CCKB receptors in mouse endothelial
cells involved in glioblastoma neoangiogenesis. Chronic
in vivo administration of a selective CCKB receptor
antagonist to mice bearing xenografts of human C32
melanoma cells significantly decreased levels of neo-
angiogenesis, resulting in considerable delays in the
growth of these C32 xenografts. In conclusion, our study
identifies the pleiotropic effects of gastrin on melanoma
cell biology.
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Introduction
In the case of metastatic melanomas, the rate of complete
and durable response remissions merely ranges from 5% to
20% and can be achieved with biochemotherapy, a process
that includes the use of biomolecules [interleukin (IL)-2 and
interferon-a] in combination with various cytotoxic agents
(dacarbazine, cisplatin, and vinblastine) [1,2]. Insulin-like
growth factors (IGFs) are among those biomolecules that
play various major roles in the biology of many cancer types
in general [3], and of melanomas in particular [4,5]. We
hypothesize that gastrin (G17) could also influence the bio-
logic behavior of human melanomas for the following rea-
sons. Reubi et al. [6] analyzed 406 human tumors of various
origins and observed that medullary thyroid carcinomas,
small cell lung cancers, and astrocytomas (three types of
cancers with ‘‘neural’’ origins) frequently express gastrin recep-
tors [i.e., the cholecystokinin (CCK)B receptor described below],
whereas their pure epithelial counterparts—differentiated
thyroid cancers of the follicular and papillary types and non–
small cell lung cancers—do not. Melanomas are also reported
to have a neural origin. Melanomas could thus express gastrin
receptors. As far as we know, neither Reubi et al. nor any other
group has investigated whether melanomas express gastrin
receptors. As recently reviewed by Rozengurt and Walsh [7]
and Dockray et al. [8] and as summarized by Lefranc et al. [9],
three receptors to which gastrin can bind have already been
cloned. The CCKA (also named CCK1) receptor is highly selec-
tive (from 500- to 1000-fold) toward the sulfated analogues of
CCK, and especially of CCK-8 [7,8,10]. The CCKB receptor
(also called CCK2 and the gastrin receptor) is less selective
than CCKA because it does not require a sulfated tyrosine resi-
due of CCK-8 [7,8,10]. Gastrin has also been reported to bind to
the 78-kDa gastrin-binding protein (GBP; i.e., the so-called
‘‘CCKC gastrin receptor’’) [11]. Several GBPs have been de-
scribed [12–16] in addition to the three cloned receptors. Al-
though human glioblastoma cells do not displayCCKA andCCKB
receptors [6,12], we demonstrated that gastrin significantly mod-
ifies cell proliferation [17–19] and migration of human glioblas-
toma cells [12,18,20,21]. In fact, we evidenced that the biologic
gastrin-mediated effects on these glioblastoma cells are medi-
ated by binding sites for the C-terminal heptapeptide of gastrin
(G17) [12]. We also emphasize that gastrin modulates pro-
liferation and apoptosis levels in a large variety of cancers origi-
nating from the gastrointestinal tract (cf. Refs. [7,10] for reviews;
also Refs. [22,23]). In addition to its roles in cell proliferation,
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apoptosis, and migration of a large variety of cancer cells,
gastrin has potent proangiogenic effects, as we recently
demonstrated in the case of experimental glioblastomas [9].
The primary objective of this study was to characterize
the presence or absence of mRNA for the CCKA, CCKB, and
CCKC receptors. This was done by means of reverse tran-
scription polymerase chain reaction (RT-PCR) techniques
(because no reliable antibodies exist for protein analysis) on
four humanmelanoma cell lines (theHT-144, C32,G-361, and
SKMEL-28 models) and seven human melanoma metas-
tases (used as a control). We then characterized in vitro the
influence of gastrin on global growth [(3-(4,5)-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric
assay], cell proliferation (flow cytometry), apoptosis (flow
cytometry), and migration by means of a separate analysis
of cell motility (quantitative videomicroscopy) and cell inva-
sion processes (Matrigel-coated Boyden chambers) in the
abovementioned human melanoma cell lines. The patterns
of matrix metalloproteinase (MMP) and integrin mRNA
expression, determined by means of cDNA microarrays,
led us to analyze the influence of gastrin on the MMP-14
and avb3 integrin levels of expression by means of Western
blot analysis and quantitative immunofluorescence. Using a
scratch wound assay, we also investigated whether gastrin
significantly modified the cytotoxic effects induced by cis-
platin and dacarbazine on human HT-144 melanoma cells.
As we had recently demonstrated the involvement of the
CCKB receptor in neoangiogenesis in experimental glio-
blastomas [9], we also investigated in this study whether a
specific CCKB gastrin receptor antagonist displayed anti-
angiogenic effects in human C32 xenografts grafted subcu-
taneously onto nude mice and subsequently influenced the
growth rates of these xenografts.
Materials and Methods
Cell Lines and Culture Media
The four human melanoma cell lines were obtained from
the American Type Culture Collection (ATCC; Manassas, VA)
and were maintained in vitro in accordance with the recom-
mendations of the ATCC. The C32 cells were cultured in mini-
mal essential medium (MEM; GibcoBRL/Life Technologies/
Invitrogen, Merelbeke, Belgium), to which 5% fetal calf serum
(FCS; GibcoBRL) was added. SKMEL-28 cells were cultured
in RPMI medium (GibcoBRL), to which 10% FCS was added.
HT-144 cells were cultured in MEM with 10% FCS, with the
addition of essential amino acids. The G-361 cells were
cultured in OPTIMEM medium (GibcoBRL), to which 5%
FCS was added.
All the media were supplemented with a mixture of
0.6 mg/ml glutamine (GibcoBRL), 200 IU/ml penicillin (Gibco-
BRL), 200 IU/ml streptomycin (GibcoBRL), and 0.1 mg/ml
gentamicin (GibcoBRL). The FCS was heat-inactivated for
1 hour at 56jC.
Human MCF-7 breast cancer cells (ATCC code HTB-22)
were used as a control for p53-induced expression.
Clinical Samples
We analyzed the pattern of gastrin receptor expression
in seven metastases from human melanoma patients who
had undergone surgery at the Erasmus University Hospital.
The seven clinical samples under study were obtained from





and dacarbazine were purchased from Sigma (Bornem,
Belgium). The L365,260 (3R-3-[NV-(3-methylphenyl)ureido]-
1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepine-
2-one) compound was provided by ML Laboratories PLC
(London, UK).
RT-PCR Analyses to Determine the CCKA, CCKB, and
CCKC Receptor mRNA
The procedure used here is identical to the one we
recently described in detail [9]. All the PCR products were
sequenced by GenoScreen (Lille, France) by means of the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Bio-
systems, Foster City, CA).
As indicated in Table 1, four primers (p1–p4) were assayed
for the CCKA, two (p5 and p6) for the CCKB, and two (p7 and
Table 1. Description of the Forward and Reverse Primers Used in the Present Study.
Targeted Gene (Human) Forward Primers Reverse Primers Location Positions PCR Product
Sizes
-Actin 5V-AAATCGTGCGTGACATTAAGG-3V 5V-CTAAGTCATAGTCCGCCTAG-3V Interexons 661–1185 525
CCKA receptor
p1 5V-GTTGACAGCCTTCTTGTG-3V 5V-CAGATTAAAGGTAGATACACTCAC-3V Interexons 163–549 387
p2 5V-TGCAAACCCTTACAGTCCC-3V 5V-CCACCATCATCACACTTCC-3V Interexons 583–835 253
p3 5V-CAACTTGGTGCCTTTTACC-3V 5V-TCCATATGCCACCATCATC-3V Interexons 693–843 151
p4 5V-CTCGTACAGCCATATGAGTG-3V 5V-GAACTGCCTAGAAACCAATC-3V Noncoding 1401–1651 251
CCKB receptor
p5 5V-TCATTCACTTGCTGAGCTAC-3V 5V-CAGTGTCATGTTTCTATGGG-3V Partly coding 1314–1774 461
p6 5V-CCCATAGAAACATGACACTG-3V 5V-GAGATTAGGCCTGATGGTATT-3V Noncoding 1755–1988 234
CCKC receptor
p7 5V-TATCACGACCGAGAAAACTT-3V 5V-CGCTACATCCACACCAACTT -3V Interexons 1559–1814 256
p8 5V-TGGATAGTATTTTAGCGAGTCTG-3V 5V-CTTCTCGTTACTCTGATAAATCTAG-3V Interexons 1981–2418 438
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p8) for the CCKC receptors. The exact locations targeted by
each of these primers with respect to the mRNA for the CCKA,
CCKB, and CCKC receptors are illustrated in Table 1.
The thermal profiles were as follows: predenaturation for
4 minutes at 95jC; denaturation for 45 seconds at 95jC;
annealing for 45 seconds at 57jC (p1, p3, and p4), 58jC (p2,
p6, p7, and p8), and 62jC (b-actin, p5); elongation for
1 minute and 15 seconds at 72jC; and a final elongation for
10 minutes at 72jC. The PCR products were obtained after
40 thermal cycles, with the exception of the b-actin, which
was obtained after 30 thermal cycles.
cDNA Microarray to Determine the mRNA Patterns of
Expression for Metalloproteinases and Integrins in Human
Melanoma Cells
The method that we used to check the quality of the
extracted RNA before submitting the four human melanoma
cell lines under study to the metalloproteinase- and integrin-
related cDNA microarray approach and to this cDNA micro-
array approach is described in detail elsewhere [9].
We used two types of microarrays provided by Super-
array (Bethesda, MD), referred to as the ‘‘GEArray Original
Series Human Integrin Gene Array’’ and the ‘‘GEArray Origi-
nal Series Human Metalloproteinase Gene Array.’’ These
arrays are designed to assess the expression levels of 15
a-integrin and 8 b-integrin subunits, in addition to 19 metallo-
proteinases and 3metalloproteinase tissue inhibitors (TIMP-1,
TIMP-2, and TIMP-3) spotted in duplicate. The array kits were
used, in accordance with the procedures recommended by
the manufacturer, to assess the levels of gene expression in
equal amounts of total RNA extracted from human HT-144
melanoma cells (cf. Figures 2B and 3C). The hybridization
results were visualized by a Fuji-BAS5000 scanner, and the
relative amounts of mRNA transcripts were quantified using
an AIDA image analyzer software (Raytest Benelux, Tilburg,
The Netherlands).
Western Blot Analyses [MMP-14, p53, PTEN,
poly(ADP-ribose) polymerase (PARP), Akt,
phospho-Akt, and mTOR]
Cell extracts were prepared from lyses of subconfluent
cells in ice-cold phosphate-buffered saline (PBS) containing
a MiniComplete protease inhibitor cocktail (Roche Diag-
nostics, Mannheim, Germany). Twenty micrograms of pro-
teins (evaluated by the BCA protein assay; Pierce/Perbio
Science, Erembodegem, Belgium) was loaded onto a
denaturating polyacrylamide gel (10%) and blotted onto a
Polyscreen*PVDF membrane (NEN Life Science Products,
Boston, MA). The Akt (dilution 1/1000), Ser 473p-Akt (dilution
1/1000), Thr 308p-Akt (dilution 1/500), mTOR (dilution 1/1000),
and PTEN (dilution 1/750) antibodies were purchased from
Cell Signaling (Beverly,MA);MMP-14 antibody (dilution 1/50)
was from Oncogene Research Products (Calbiochem/VWR,
Leuven, Belgium); p53 antibody (dilution 1/1000) was from
Calbiochem; and rat tubulin (dilution 1/2000) was from
Abcam (Cambridge, UK). The secondary antibodies were
purchased from Pierce, with the exception of the rabbit anti-
rat antibody, which was supplied by Abcam.
The integrity and quantity of the extracts were determined
by means of tubulin immunoblotting. Blots were developed
using the Pierce Supersignal Chemiluminescence system
(Perbio Science).
Determination of Protein Expression by Quantitative
Fluorescence
Fluorescent detection of protein expression in cells cul-
tured on glass coverslips was performed as previously de-
scribed [9,19,21,24]. The specific binding of the primary
antibodies was detected by Alexa Fluor 488– or Alexa Fluor
594–conjugated secondary antibodies (10 mg/ml; Molecular
Probes, Inc., Eugene, OR). Fluorescent phallacidin conju-
gated to Alexa Fluor 488 fluorochrome (Molecular Probes,
Inc.) was selected to label the fibrillar actin, and Alexa Fluor
594–conjugated DNAseI (Molecular Probes, Inc.) was cho-
sen to stain the globular actin to conduct an investigation
into the organization of actin cytoskeleton. av and b3 integrin
antibodies were provided by BD Transduction Laboratories
(Erembodegem, Belgium) and were used at 1/100 dilution.
The staining protocols are described elsewhere [9,19,21,24].
The fluorescence intensities of the fluorochromes were
quantified by a computer-assisted fluorescent Olympus
AX70 microscope (Omnilabo, Antwerp, Belgium), equipped
with a Megaview2 digital camera and an analySIS software
(Soft Imaging System, Munster, Germany), as described in
detail elsewhere [9,19,21,24]. All the cells for analysis were
selected using the computer mouse to draw contours on the
video screen (connected to the computer-assisted micro-
scope) based on a phase-contrast image. One hundred cells
were quantified for each experimental condition.
In Vitro Overall Growth Determination
The four human melanoma cell lines were incubated in
96-microwell plates for 24 hours (at a concentration of
40,000 cells/ml culture medium) to ensure adequate plating
prior to the determination of cell growth. The influence of
gastrin on overall growth rates of the four human melanoma
cell lines under study was determined by means of the color-
imetric MTT assay, as previously described [17,19]. Each
experiment was conducted in sextuplicate. Nine concentra-
tions ranging from 1012 to 108 M (with a semilog decrease
in concentration) were assayed for gastrin.
Flow Cytometry Analyses to Determine Apoptotic Versus
Nonapoptotic-Related Cell Death in Human HT-144 and
C32 Melanoma Cells
Flow cytometry analyses of apoptotic-related versus
nonapoptotic-related HT-144 and C32 cell death were per-
formed in accordance with the experimental protocol de-
scribed in detail by Darzynkiewicz et al. [25]. In summary,
after various treatments with gastrin and cytotoxic drugs
[such as cisplatin (cf. Figure 4E and its legend) and dacarba-
zin; data not shown], the cells were incubated in darkness in
an Annexin V–FITC (V) and propidium iodide (PI) solution for
15 minutes at 4jC (Annexin V–FITC Kit; Immunotech, Mar-
seille, France). Data from around 10,000 cells were recorded
on a logarithmic scale for each sample. An ‘‘XL System II’’
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(Beckman Coulter, Miami, FL) was used to give a precise def-
inition of both the percentage of cells in the apoptotic and/or
nonapoptotic compartments and the percentage of normal
cells (i.e., those that apparently remained unaffected by the
various treatments). The so-called normal cells were negative
for both the Annexin V and PI staining, whereas the apoptotic
cells were positive for Annexin V but negative for PI. The non-
apoptotic cells (whose cell membranes have holes) were
positive for both PI and Annexin V. Each experiment was
conducted in triplicate.
The cell cycle kinetics of the HT-144 and C32 melanoma
cells treated with gastrin or left untreated was determined by
flow cytometry analyses of the PI nuclear staining, as de-
scribed in detail by de Launoit et al. [26].
In Vitro Invasion Assay
The Boyden transwell invasion system (BD BioCoat
Matrigel invasion chambers; BD Biosciences Discovery
Labware, Bedford, MA) was used to evaluate cell invasive-
ness. These invasion chambers were divided into two
compartments separated by an 8-mm pored polyethylene
membrane coated with Matrigel (10 mm thickness). After
rehydration of the inserts, between 40,000 and 60,000 cells
(depending on the melanoma cell type) in 500 ml of serum-
supplemented medium were seeded in the upper cham-
bers, whereas the lower chambers were filled with 500 ml
of serum-supplemented medium. G17 was added to the
upper compartment at concentrations ranging from 1012
to 108 M immediately after the seeding process. The cells
were allowed to invade through the matrix at 37jC for
24 hours. The noninvading cells remaining on the upper
surface of the coated membrane were removed with a
cotton-tipped swab. The invading cells on the lower surface
of the membrane were fixed, stained with Diff-Quick
(Merz+Dade AG, Baxter, Belgium), and counted with an
inverted-phase contrast microscope.
To further normalize the data in accordance with cell
growth, the experimental conditions of eachBoyden chamber
were reproduced simultaneously in a 24-well plate coated
with Matrigel. The invasive rate was obtained by reporting the
number of invading cells in each Boyden chamber compared
with the total number of cells in the corresponding well,
computed with a cell counter (Coulter-Particle-Counter-Z2;
Analys, Ghent, Belgium) after trypsin treatment. Each exper-
iment was conducted in triplicate.
In Vitro Motility Assay
Human melanoma cell motility levels were characterized
using a device (described elsewhere) [18,21,27] that enables
the quantification of the trajectories of living cells maintained
in culture. The greatest linear distance migrated by each cell
was calculated based on these trajectories. This distance is,
in fact, the maximum relative distance from the point of origin
[i.e., the maximum relative distance to the origin (MRDO)
quantitative variable] [18,21,27]. All the experiments were
performed over 8 hours, and one image was recorded every
4 minutes. Because the analyses were conducted in tripli-
cate, a minimum of 82 cells and a maximum of 170 cells were
analyzed in each experimental condition. Analyses in tripli-
cate imply that each experiment was conducted indepen-
dently three times. The effect of gastrin on human melanoma
cell motility levels was analyzed from 1012 to 108 M.
In Vitro Scratch Wound Assay
The HT-144 melanoma cells were grown to confluence in
six-well dishes. The cells were then pretreated with 10 nM
gastrin for 1, 3, 7, or 24 hours in a serum-restricted medium
(5%). Scratch wounds were made by creating a linear de-
nuded region using a pipette tip (as illustrated in Figure 4, A
and B and their legends). The cells were washed twice
with PBS prior to their incubation with the cytotoxic agent
(cisplatin or dacarbazine) at 0.1, 1, and 10 mM in a serum-
restricted medium for 62 additional hours of postgastrin
treatment. Four fields per well were photographed twice daily
until wound healing was observed in the control. A software
developed in our laboratory was used to quantify the area
filled by the cells (within the frame illustrated in Figure 4, A
and B) over the period of the experiment.
Characterization of the Effects Induced In Vivo by a Gastrin
Antagonist on the Growth and Level of Neoangiogenesis
in Human C32 Melanoma Cells Xenografted
Subcutaneously onto the Flanks of Nude Mice
The effects induced in vivo by gastrin receptor antagonist
L365,260 were determined in neoangiogenesis in subcuta-
neous human C32 melanoma xenografts by administering
L365,260 (10 mg/kg, i.p.) five times a week for eight con-
secutive weeks. Treatments started on the 14th day post-
tumor graft.
SubcutaneousC32 xenografts were performed by grafting
2  106 C32 human melanoma cells onto the left flanks of
8-week-old female nu/numice (weight 21–23 g; BioServices,
Uden, The Netherlands). We chose the C32 model from the
four human melanoma models under study due to the highly
reproducible tumor developments (100%) obtained for this
model; no such success rates were ever obtained for the
remaining three models (data not shown).
Tumor size was measured twice weekly by means of a
caliper and expressed as an area (square millimeters) by
multiplying the two largest perpendicular diameters. We were
thus able to evaluate the potential antiangiogenic L365,260-
induced effects on C32 tumor growth rates. Because the aver-
age tumor size had attained 500 mm2 in the control group,
the endpoint of the C32-related in vivo experiments was the
sacrifice, for ethical reasons (in a CO2 atmosphere), of all the
nude mice bearing subcutaneous xenografts on the 85th day
posttumor graft. The tumors were removed, fixed in buffered
formalin for 5 days, embedded in paraffin, and cut into 5-mm-
thick sections; histologic slides were stained with hematoxylin
and eosin for vessel counts (cf. Figure 5B). We also investi-
gatedwhether the L365,260 treatmentmodifiedC32 tumor cell
heterogeneity or proliferation. We used an anti-p53 antibody
(Dakocytomation, Glostrup, Denmark) to analyze the effects
of L365,260 on tumor cell heterogeneity and the MIB-1 anti-
body (Dakocytomation), which targets the Ki-67–related cell
proliferation marker, to analyze cell proliferation levels.
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All the in vivo experiments described in the current study
were performed based on authorization no. LA1230509 of
the Animal Ethics Committee of the Federal Department of
Health, Nutritional Safety, and the Environment (Belgium).
Characterization of the Patterns of Immunohistochemical
Expression of S100B and HMB-45 to Prove That the Human
Melanoma Cell Lines Used Here Exhibited Actual
Characteristics of Human Melanoma
We used anti-S100B and anti-HMB45 antibodies (Bio-
genex, San Ramon, CA) to investigate whether the C32 and
HT-144 human melanoma models used in this study still
exhibited the actual biologic characteristics of human mela-
nomas. The immunohistochemical procedures were identical
to those previously described in detail [28].
Statistical Analyses
Statistical comparisons were made by conducting the
Kruskal-Wallis test (a nonparametric one-way analysis of
variance). Where this test revealed some significant differ-
ences, we compared pairs of groups by applying the Mann–
Whitney U test. All the statistical analyses were performed
using Statistica (Statsoft, Tulsa, OK).
Results
Characterization of mRNA Expressions for the CCKA,
CCKB, and CCKC Receptors in Four Human Melanoma
Cell Lines and Seven Clinical Samples
Figure 1 illustrates the mRNA expression pattern of the
CCKA (Figure 1, A and B), CCKB (Figure 1, C and D), and
CCKC (Figure 1,E and F ) receptors in four humanmelanoma
cell lines (lanes 4–7 in Figure 1, A, C, and E ) and seven
human melanoma metastases (lanes 8–14 in Figure 1, B, D,
and F ) assessed by means of RT-PCR. The four cell lines
include the HT-144, G-361, C32, and SKMEL-28 models. An
RT-PCR for b-actin was performed using all the extracts as
quality control (Figure 1, G and H).
Figure 1, A and B shows that in the four melanoma cell
lines and the seven humanmelanomametastases, primer p2
(cf. Table 1) failed to evidence anymRNA for CCKA. Lane 3 in
Figure 1, A and B represents the positive control in the shape
of a specimen of gallbladder tissue. Primer p1 (cf. Table 1)
also failed to evidence any mRNA for CCKA in human
melanoma cell lines and clinical samples of melanoma me-
tastases (Table 2), whereas primers p3 and p4 (Table 1) re-
vealed the presence of parts of the CCKA receptor mRNA in
these biologic samples (Table 2).
Figure 1, C and D shows that CCKB receptor mRNA can
be evidenced in human melanoma cell lines as well as in
clinical samples of human melanoma metastases; however,
these data were obtained with primer p6, which was located
in a noncoding region of the CCKB receptor (cf. Table 1). In
contrast, primer p5 evidenced CCKB receptor mRNA in only
one of the seven melanoma metastases and in none of the
four human melanoma cell lines (Table 2).
Thus, because two or three of the four primers used here
to target the CCKA receptor mRNA failed to demonstrate the
presence of any mRNA, the present data strongly suggest
that functional CCKA receptors were neither present in the
four human melanoma cell lines under study nor in the seven
clinical samples of human melanoma metastases. The same
conclusion may be drawn for the CCKB receptor. These con-
clusions are supported by functional studies because we
observed no significant binding of radioiodinated CCK or
gastrin in any of the four human melanoma cell lines under
study (data not shown). These functional studies were con-
ducted by means of radioactive binding assays, as described
in detail elsewhere [12]. We did not succeed in demonstrat-
ing either the presence or absence of the CCKA and CCKB
receptors at protein level in the four human melanoma cells
lines because the only commercially available antibodies
against the CCKA and CCKB receptors failed to reveal the
presence of any CCKA receptors in the human gallbladder
tissue (reference tissue; data not shown) and of any CCKB
receptors in the human brain tissue (reference tissue; data
not shown).
Figure 1, E and F shows that primer p7 (cf. Table 1)
revealed the presence of CCKC receptor mRNA in each
sample tested, as did primer p8 (Tables 1 and 2). These data
suggest that this third type of receptor, with its ability to bind
gastrin, might be responsible for part of the gastrin-mediated
biologic effects on human melanoma cells, as described in
detail below. There are no commercially available antibodies
that reveal the CCKC receptors at protein level.
Characterization of the Influence of Gastrin on Overall
Growth Rates, Cell Cycle Kinetics, Motility Levels, and the
Organization of Actin Cytoskeleton in the Four Human
Melanoma Cell Lines under Study
In vitro, gastrin did not significantly modify overall growth
rates (for concentrations ranging from 1012 to 108 M) in the
four human melanoma cell lines under study (data not
shown). Gastrin did not therefore significantly modify cell
cycle kinetics (i.e., the percentages of tumor cells in the G1,
S, and G2/M phases of their cell cycles) in the cell lines under
study (data not shown).
Cell migration is a very complex biologic process [29,30]
that incorporates cell adhesion [interactions between the
cells and the extracellular matrix (ECM)] [31,32], cell motility
(cell movement that is dependent on the organization of the
actin cytoskeleton in relation to the attachment to the ECM
components) [33,34], and invasion (the process of biologic
degradation, as illustrated in the ‘‘Characterization of the
Influence of Gastrin on the Invasiveness Levels of Human
Melanoma Cells and Expression of MMP-14’’). Figure 2A
shows that gastrin significantly modifies motility levels in HT-
144 and C32 human melanoma cells, but not in G-361 and
SKMEL-28 cells.
Integrins, which are dimeric transmembrane glycoproteins
linking the intracytoplasmic actin cytoskeleton to the ECM
components during cell migration [29–34], also play various
major roles in melanoma cell migration [35,36]. Figure 2B
illustrates the pattern of integrin mRNA expression in human
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HT-144 cells on which gastrin exerts a potent antimotility ef-
fect (Figure 2A). avb3 integrin plays various important roles
during the transition of melanoma cells from the radial to the
vertical growth phase [35,36]. Figure 2B shows that avb3
integrin was well expressed in the HT-144 cells, at least at the
mRNA level, as was also the case for the other three human
melanoma cell lines under study (data not shown). Figure 2C
shows that, in HT-144 cells, 10 nM gastrin significantly
decreased the levels of expression (at protein level) of both
av and b3 integrin subunits. The gastrin-induced decrease in
the expression of the av and b3 integrins in the HT-144 cells
(Figure 2C) could at least partly explain the gastrin-induced
decrease in the motility levels of these cells (Figure 2A). In
fact, minor modifications to the forces generated by the ad-
hesion of specific types of integrins to various components of
the ECM can markedly modify cell migration rates [37].
As indicated above, the organization of the actin cyto-
skeleton is crucial for cell migration, and gastrin is able to
modulate the organization of the actin cytoskeleton through
multiple pathways [7,21]. Figure 2, D and E illustrates the
actin cytoskeleton pattern in the untreated HT-144 cells
(Figure 2D) and in the HT-144 cells treated with 10 nM gastrin
Figure 1. Illustration of the mRNA expression pattern of the CCKA, CCKB, and CCKC receptors in four human melanoma cell lines (lanes 4–7 in A, C, and E) and
seven human melanoma metastases (lanes 8–14 in B, D, and F) assessed by means of RT-PCR. Lane 1: kilobase plus ladder; lane 2: negative control; lane 3:
gallbladder tissue (positive control for the CCKA receptor); lane 4: HT-144 cell line; lane 5: G-361 cell line; lane 6: C32 cell line; lane 7: SKMEL-28 cell line. (A and
B) The results obtained with primer p2, which we used for the CCKA receptor (cf. Table 1). (C and D) Those obtained with primer p6, which we used for the CCKB
receptor (cf. Table 1). (E and F) Those obtained with primer p7, which we used for the CCKC receptor (cf. Table 1). An RT-PCR for -actin was performed with all
the extracts as quality control (G and H).
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for 3 hours (Figure 2E ). Figure 2F illustrates the log fibrillar (F)
actin/globular (G) actin ratio in the untreated (Ct condition)
HT-144 cells or in the cells treated with 10 nM gastrin for 3
and 12 hours; the data show that gastrin markedly increased
the proportion of fibrillar actin to the detriment of globular
actin—a factor that could rigidify the actin cytoskeleton and
may, in turn, decrease the suppleness required for optimal
migration (cf. Figure 2A).
Characterization of the Influence of Gastrin on the
Invasiveness Levels of Human Melanoma Cells
and Expression of MMP-14
Gastrin significantly decreased the invasiveness levels of
the HT-144 (Figure 3A), G-361 (Figure 3B), and SKMEL-28
(data not shown) humanmelanoma cells in a dose-dependent
manner. This was not, however, the case for the C32 cells,
which exhibited no invasive abilities in the context of the
Matrigel-coated Boyden chambers (data not shown).
We wished to ascertain whether gastrin was able to modify
the levels of expression of one or other MMPs becauseMMPs
play various crucial roles in invasion processes. Figure 3C
shows that of the MMPs expressed by the HT-144 cells,
MMP-14, MMP-15, MMP-16, and MMP-20 were strongly ex-
pressed, at least at mRNA level, as were TIMP-1, TIMP-2,
and TIMP-3. Similar patterns of expression were observed
for the remaining three cell lines under study (data not
shown). As described in detail in the ‘‘Discussion,’’ there
are several studies that clearly indicate the involvement
of MMP-14 in the biologic aggressiveness of melanomas
[38–41]. We therefore investigated whether gastrin is able
to modify the levels of expression of MMP-14 in HT-144 cells.
Figure 3D clearly indicates that 10 nM gastrin (but not 0.1 nM)
significantly decreased the levels of expression of MMP-14
Table 2. Rundown of the Data on the Various Primers Set Up to Evidence
the Presence of CCKA, CCKB, and CCKC Receptor mRNA in the Four Human
Melanoma Cell Lines and in the Seven Clinical Samples (the Primers Used
are Described in Table 1).
Receptors CCKA-R CCKB receptor CCKC receptor
Primers p1 p2 p3 p4 p5 p6 p7 p8
Cell lines
HT-1444    +  + + +
G-361      + + +
C32    +   + +
SKMEL-28   + +  + + +
Clinical samples
CS-1   + +  + + +
CS-2    +  + + +
CS-3    +  + + +
CS-4      + + +
CS-5    +  + + +
CS-6    +  + + +
CS-7   + + + + + +
The exact locations in the mRNA of the three receptors targeted by the
various primers are illustrated in Table 1.
Figure 2. (A) Determination of the influence of gastrin onmotility levels (quantified bymeans of computer-assisted phase-contrast microscopy) in the HT-144, G-361,
C32, and SKMEL-28 human melanoma cells. The motility levels are related to the maximum relative distance from the point of origin (in m/hr) traveled by each cell
analyzed individually over an 8-hour period of observation. The control value was arbitrarily normalized to ‘‘0%.’’ (B) HumanHT-144melanoma cells were subjected to
a cDNA microarray to determine the pattern of integrin-specific RNA expression. (C) Characterization of the influence of 10 nM gastrin (G17) on the levels of
expression of av (gray bars in C) and 3 (black bars in C) integrin subunits in HT-144 humanmelanoma cells 24 hours after the addition of gastrin to the melanoma cell
culture medium. The levels of integrin subunit expression were determined by means of computer-assisted fluorescence microscopy. (D and E) The morphologic
appearance of fibrillar (green fluorescence) as opposed to globular (red fluorescence) actin in the cytoskeletons of the untreatedHT-144 cells (D) and those treated for
3 hours with 10 nM G17 (E). The ratio of fibrillar/globular actin was quantitatively determined by means of computer-assisted fluorescence microscopy (F). The data
are presented as means (thick bars) ± standard error of the mean (thin bars). **P < .01 and ***P < .001 in comparison with the control.
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for between 9 and 33 hours after its addition to theHT-144 cell
culture medium.
Characterization of the Influence of a Combination of
Gastrin and a Cytotoxic Agent (Cisplatin or Dacarbazine)
on the In Vitro Development of Human HT-144 Melanoma
Cell Populations
The data reported in the previous sections clearly indicate
that gastrin has somemarked antimigratory effects on human
HT-144 melanoma cells, without affecting their proliferation,
however. We therefore investigated what occurs in the de-
velopment of human HT-144 melanoma cell populations
(taking cell proliferation, death, and migration into consider-
ation) when gastrin is combined with a cytotoxic agent. We
used the scratch wound assay that enables cell migration,
proliferation, and death to be analyzed together. Figure 4A
shows the result of a scrapping procedure on a subconfluent
HT-144melanoma cell population and the results (Figure 4B)
of a successful colonization (‘‘wound healing’’) of the ‘‘me-
chanical wounds’’ by migrating and proliferating HT-144
cells. Figure 4C illustrates the effects of gastrin pretreatment,
which precedes cytotoxic treatment on the wound healing
phenomenon. The wound healing surface filled by HT-144
cells cultured in the absence of gastrin and cisplatin was
arbitrarily normalized to 100% of wound colonization. The
duration of gastrin pretreatments at 10 nM is represented on
the x-axis, with ‘‘0’’ corresponding to the absence of gastrin
pretreatment. In this last condition, cisplatin used at 0.1 mM
(black squares) or 10 mM (black dots) reduced wound
healing by 4% and 12%, respectively (compared to the
arbitrary 100% control value), a result that did not attain
a statistical level of significance (P > .05) compared to the
control. In sharp contrast, the addition of 10 nM gastrin to the
culture medium of the HT-144 cells 3 hours (‘‘3’’), 7 hours
(‘‘7’’), or 24 hours (‘‘24’’) prior to theaddition of 0.1 or 10 mM
cisplatin markedly decreased (P < .01) the ability of these
HT-144 cells to colonize the wounds, whereas treatment with
10 nM gastrin alone over a 24-hour period did not contribute
more than 20% (P < .05) of wound healing inhibition (data
not shown). A significant additive effect on the abilities of
the HT-144 cells to colonize wounds (Figure 4C) has already
been obtained by treatment with 10 nM gastrin for 1 hour
prior to the addition of cisplatin. We obtained identical data
when combining dacarbazine with gastrin (data not shown).
Several types of highly malignant and migrating cells, such
as glioblastoma cells [31], are protected against apoptosis,
and the experimentally induced decrease in migration levels
of rapidly migrating cancer cells can restore a certain level of
sensitivity of these cancer cells to proapoptotic agents, such
as cytotoxic ones [31]. Gastrin has been reported to have
antiapoptotic effects on different types of cells [22,23,42]; in
this study, we observed that gastrin markedly decreased the
levels of migration of HT-144 melanoma cells. As illustrated
below, HT-144 cells are resistant to apoptosis. We therefore
wished to ascertain whether, in the case of these highly
migrating HT-144 melanoma cells, gastrin could restore a
certain degree of sensitivity to apoptosis in relation to the
gastrin-induced decrease in HT-144 cell migration, or whether
Figure 3. Characterization of the influence of gastrin (from 1012 to 108 M) on the invasiveness (in Boyden chambers coated with Matrigel) of HT-144 (A) and
G-361 (B) human melanoma cells. (C) HT-144 human melanoma cells were subjected to a cDNA microarray to determine the pattern of MMP-specific RNA
expression. (D) The gastrin-induced effects on the MMP-14 expression. Western blot analysis was performed 9, 24, and 33 hours after the addition of 0.1 and
10 nM gastrin (except in the control, Ct) to the culture medium of human HT-144 melanoma cells.
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gastrin would continue to have an antiapoptotic effect on the
HT-144 cells despite the fact that it is able to significantly de-
crease the migration rates of these cells.
Figure 4D shows that the basal expression of the p53
protein in the HT-144 andC32melanoma cells is low (or even
absent) and that a cytotoxic insult with adriamycin (10 mM)
increases its expression, suggesting the potential presence
of functional p53 protein in thesemelanoma cells. In contrast,
HT-144 and C32 melanoma cells did not express any PTEN
gene product, a factor that would render them resistant to
apoptosis (Figure 4D). The data illustrated in Figure 4E fully
support this hypothesis. In fact, the open bars in Figure 4E
Figure 4. Therapeutic combination of gastrin and cytotoxic agents in scratch wound assay. Colonization of a mechanical wound in a subconfluent HT-144 cell
population (cf. black rectangles in A) was followed over time (complete wound healing is shown in B). (C) The delay in the wound healing process obtained when
HT-144 cells were submitted to gastrin treatment [10 nM; duration of the gastrin exposure varied from 0 hour (no gastrin treatment) to 24 hours on the x-axis] before
the cytotoxic insult with cisplatin used at 0.1 M (black squares) or 1 M (black dots). Control took the shape of HT-144 cells cultured in the absence of gastrin and
cisplatin and was arbitrarily normalized to 100% of wound colonization after 62 hours of culture. (D) Western blot analyses of the levels of expression of p53 and
PTEN in human MCF-7 breast cancer (positive control) and human melanoma HT-144 and C32 melanoma cells either challenged with 10 M adriamycin (ADR) or
left unchallenged. Cell death processes were investigated by means of flow cytometry and Western blot analysis for PARP, as shown in (E). The open bars in the
upper part represent normal cells (i.e., cells not in the process of dying), the black bars (located between the open and gray bars, and so thin that they are almost
invisible) represent the proportion of apoptotic cells, and the gray bars represent the proportion of cells dying from nonapoptotic processes. The bottom part of (E)
deals with the Western blot analysis. The experimental conditions on the x-axis are as follows: Ct = control; G17 = 10 nM gastrin for 24 hours; G17 6 hours + Cis =
10 nM gastrin added 6 hours before 10 M cisplatin, with PARP cleavage determination carried out 48 hours after the addition of cisplatin to the culture medium of
HT-144 cells; G17 24 hours + Cis = 10 nM gastrin 24 hours before 10 M cisplatin, with PARP cleavage determination carried out 48 hours after the addition of
cisplatin to the culture medium of the HT-144 cells. (F) Characterization over time of the effects of 10 nM gastrin on the levels of expression and activation (473Ser-
phospho-Akt) of Akt and on the levels of expression of mTOR.
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represent normal cells (i.e., cells that are not dying), the black
bars (located between the open and gray bars, and so thin
that they are almost invisible) represent the ratio of apoptotic
cells, and the gray bars indicate the ratio of cells dying from
nonapoptotic processes. These data show that death in HT-
144melanoma cells undergoing cisplatin or gastrin + cisplatin
treatment is nonapoptotic cell death because apoptosis is
not present in these cells (Figure 4E). Gastrin did not induce
any cell death at a 10-nM dose when compared to the control
cells, nor did it modify the pattern of HT-144 cell death when
compared to cisplatin alone (Figure 4E).We performedWest-
ern blot analyses of PARP [43,44] to confirm the absence of
apoptosis in HT-144 cells. PARP is a 116-kDa enzyme that
regulates chromatin structure during differentiation and DNA
repair and is prone to proteolytic cleavage, either yielding
a 85- to 89-kDa fragment during apoptosis or resulting in
50- to 62-kDa fragments during necrosis [43,44]. The data in
Figure 4E clearly indicate that 10 mM cisplatin did not induce
evident apoptosis or necrosis in the HT-144 melanoma cells,
and that 10 nM gastrin even overcame the weak effects
induced by 10 mM cisplatin.
Resistance to cell death in many types of cancers is partly
related to constitutive activation of the interlinked phospho-
inositide 3-kinase (PI3-K) [31,45], Akt [31,46,47], mTOR [31],
and NF-nB [31,47] signaling pathways, and to the fact that
thePTEN gene is no longer active, as is the case with HT-144
cells (Figure 4D). PTEN inactivation in HT-144 cells should
therefore result in basal activation of the Akt in these cells.
This is the case, as is illustrated in Figure 4F. In fact, the basal
expression of Akt and mTOR is high in HT-144 cells in which
activated forms of 473Ser-phospho-Akt (Figure 4F ) and
308Thr-phospho-Akt (data not shown) are also present even
Figure 5. The effects of the L365,260 CCKB gastrin receptor antagonist on neoangiogenesis in C32 human melanoma cell xenografts (A). The black dots represent
the tumor size of the control group, whereas the white squares represent the one in the group treated with the L365,260 product (10 mg/kg five times a week during
an 8-week period). The L365,260-induced decrease in tumor growth can be related to a significant decrease in angiogenesis evidenced by the quantification of the
vessels (illustrated in B; cf. black arrow) shown in the upper panel of (A) (Ct: control group; L365: treated group). The expression patterns of p53 and Ki-67 in C32
xenografts are illustrated in (C) (G 400) and (D) (G 200), respectively. The immunohistochemical stainings for HMB45 in C32 (E; G 400) and HT-144 (F; G
400) tumors as well as for S100B (G; G 200) (H; G 400) confirmed the melanoma origin and the melanoma biologic features of these xenografted models.
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though the cells have not been submitted to any cytotoxic
insults (i.e., in control, Ct). All these data thus show that
human HT-144 cancer cells are protected against apoptosis
by defects in the expression of the PTEN gene product, with
the concomitant activation of Akt (and also the basal activa-
tion of mTOR). All these data together thus show that the
gastrin-induced decrease in melanoma cell migration did not
restore a significant level of sensitivity to apoptosis in these
migratory-restricted melanoma cells. It is, however, undeni-
able that the antimigratory effects contributed by gastrin had
a significant additional negative effect on the cytotoxic ef-
fects of cisplatin or dacarbazine on the in vitro development of
HT-144 melanoma cells, when compared to the negative ef-
fects of cytotoxic drugs alone on such development.
Characterization of the Influence of a CCKB Gastrin
Receptor Antagonist on In Vivo Neoangiogenesis in
Human C32 Xenografts
We were the first to recently evidence that gastrin has
potent proangiogenic effects and that the CCKB gastrin recep-
tor antagonist L365,260 contributes a significant amount of
therapeutic benefit in the case of an orthotopic model of a
human glioblastoma xenograft [9]. Bearing in mind that neo-
angiogenesis plays various crucial roles in the development of
human melanomas [48,49], we therefore wondered whether
this finding could be extended to human melanoma xeno-
grafts. Figure 5A shows that chronic treatment with L365,260
(40 intraperitoneal administrations of 10mg/kg over a 2-month
period of treatment; P < .01) decreased the growth of the C32
human xenografts very significantly, knowing that C32 human
melanoma cells did not express CCKB receptors (Figure 1 and
Table 2), unlike endothelial cells [9]. We thus counted the
vessels, as illustrated in Figure 5B (cf. black arrow), to assess
the levels of neoangiogenesis in the control (Ct), as opposed
to the L365,260 (L365)–treated C32 xenografts. The upper
panel in Figure 5A shows that chronic L365,260-related treat-
ment (P < .001) decreased the neoangiogenesis levels in the
C32 human melanoma xenografts very significantly—a fea-
ture to be analyzed concomitantly with the L365,260-induced
decrease in C32 xenograft growth (Figure 5A).
The L365,260 treatment induced no statistically significant
(P > .05) modifications to the percentages of p53-immuno-
positive cells in the C32 melanoma xenografts, when com-
pared to the control cells (data not shown); the p53 pattern of
immunostaining in a C32 xenograft is morphologically illus-
trated in Figure 5C. This suggests that the L365,260 treat-
ment did not modify the C32 tumor cell heterogeneity pattern
(i.e., it did not act specifically on any cell subpopulation pres-
ent in the C32 xenografts). The L365,260 treatment also
failed to significantly modify cell proliferation levels in the
C32 xenografts (data not shown), as assessed by MIB-1
immunohistochemical analyses (targeting the Ki-67 cell
proliferation–related antigen), which is morphologically illus-
trated in Figure 5D.
Figure 5, E–H clearly indicates that the HT-144 and
C32 human melanoma models retained biologic properties
characteristic of human melanomas. In fact, both the C32
(Figure 5E ) and HT-144 (Figure 5F ) in vivo xenografts
exhibited a significant immunohistochemical expression
of the HMB45 antigen, as was also the case for S100B
[Figure 5, G (C32 xenograft) and H (HT-144 xenograft)].
Discussion
As emphasized by Satyamoorthy et al. [4,5] and Lazar-
Molnar et al. [49], cell proliferation, differentiation, adhesion,
migration, invasion, apoptosis, stromal formation, and angio-
genesis in melanomas are modulated by crosstalks between
melanoma cells and their microenvironment through growth
factors and cytokines. These authors [4,5,49] report that the
basic fibroblast growth factor IGF-1, the platelet-derived
growth factors A and B, the transforming growth factors a
and b, IL-8, the vascular endothelial growth factor, and the
hepatocyte growth/scatter factor are to be found primarily
among these factors and cytokines. This study strongly
suggests that gastrin can be added to the list of biologic
factors that modify melanoma cell biology. In fact, although
human melanoma cells seem not to express conventional
gastrin receptors (i.e., CCKA and CCKB receptors; cf.
Table 2), gastrin nevertheless markedly modifies the migra-
tion factors in various human melanoma cell lines, as is also
the case in human glioblastoma cells [12,18,20,21] in which
CCKA and CCKB receptors are absent [6,12,19,21]. Unlike
in human glioblastoma cells where gastrin modifies cell
proliferation [17–19], gastrin does not seem to induce any
modifications to the growth rates of humanmelanoma cell lines.
Gastrin-induced modifications to human melanoma cell mi-
gration could be mediated by the CCKC receptor (cf. Table 2).
Gastrin-induced decrease in human melanoma motility
levels might have been partly related to the fact that gastrin
decreased the levels of expression of both the av and b3 in-
tegrins, which are known to play various important roles in
melanoma cell migration [50,51], and to the fact that gastrin
modified the organization of the actin cytoskeleton in these
human melanoma cells. Sturm et al. [51] report that the ex-
pression of the b3 integrin subunit in melanomas in situ
has been found to correlate with tumor thickness, ability to in-
vade and metastasize, and poor prognosis.
We had already evidenced gastrin-induced modifications
to the organization of the actin cytoskeleton of human mela-
noma cells in human glioma cells [21]. The fact that gastrin
is capable of significantly modifying the organization of the
actin cytoskeleton is actually a familiar phenomenon that
occurs through gastrin-induced activation of PI3-K–, protein
kinase C–, and small GTPase–related pathways [7]. In fact,
gastrin-induced modifications to the actin cytoskeleton in-
clude gastrin-induced effects on the p60Src/p125FAK com-
plex, which acts upstream of the gastrin-stimulated PI-3K
kinase pathway [52]. In this study, we observed that gastrin
significantly increased the proportion of stress fibers in the
HT-144 cells. Taniguchi et al. [53] not only observed similar
features in NIH3T3 fibroblasts into which the CCKB/gastrin
receptor had been introduced through an eukaryotic ex-
pression vector, but also the fact that CCK (a gastrin-related
peptide) regulated actin stress fiber formation through
the CCKB receptor in a rho p21-dependent manner. The
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gastrin-induced effects that we observed at the levels of
human melanoma cell motility and actin cytoskeleton orga-
nization could not relate to the CCKB/gastrin receptors be-
cause neither this type of receptor nor the CCKA receptors
were present in the human melanoma cells that we studied
(cf. Table 2). The possibility thus remains that these gastrin-
related effects were mediated, at least in part, through the
CCKC receptor or through someGBP, such as theG7 binding
site that we recently evidenced in glioma cells [12], or even
through an as yet unknown GBP that was more or less
specific to melanoma cells.
The gastrin-induced modifications to HT-144 melanoma
cell invasiveness through Matrigel seem to be related, at least
in part, to gastrin-induced decreases in the levels of expres-
sion of MT1–MMP (MMP-14). We decided to concentrate
our attention onMMP-14 because it plays various crucial roles
in remodeling connective tissue matrices through its ability
to initiate zymogen activation cascades, including the activa-
tion of pro-MMP-2 and pro-MMP-13 and, indirectly, pro-
MMP-9 [41]. Active MT1–MMP is inserted into the plasma
membrane with the catalytic domain facing the extracellular
space where it can cleave pericellular substrates [41]. The
gastrin-induced effects observed here in the case of MMP-14
did not modify the levels of expression and/or activation of
MMP-2 and MMP-9 in the HT-144 cells because these two
metalloproteinases are expressed weakly, if at all, in HT-144
cells (data not shown). The possibility thus remains that the
gastrin-induced decrease in HT-144 cell invasiveness related
either to a direct gastrin-induced decrease in the MMP-14
levels of expression or to a gastrin-induced decrease in the
MMP-14–mediated activation of the pro-MMP-13, or both.
Although the gastrin-mediated regulation of MMP expression
has already been demonstrated in human AGS gastric cancer
cells in the case of MMP-9 [54], a gastrin-mediated regulation
of MMP-14 expression, to our knowledge, has not yet been
reported. Gastrin stimulates PI3-K activity [7]. PI3-K is an
important regulator of vasculogenic mimicry in aggressive
melanoma cells and specifically affects MT1–MMP and
MMP-2 activities [40]. The possibility therefore remains that
part of the gastrin-mediated effect on MT1–MMP expression
in HT-144 melanoma cells (and, subsequently, on their inva-
siveness through Matrigel) could be mediated by PI3-K.
Our data on MMP-14 can also be analyzed concomitantly
with those reported by Naglich et al. [38], who used murine
B16BL6 melanoma cells injected into the bloodstream of
mice to induce experimental lung metastases. This mouse
melanomamodel expressed MMP-2 andMMP-14; treatment
with BMS-275291, a sulfhydryl-based MMP inhibitor of mice
bearing B16BL6 melanoma-related lung metastases, re-
sulted in a significant decrease in MMP-2 and MMP-14 levels
of expression and, consequently, in significantly decreased
metastasis formation [38].
It is interesting to note that MMP-14 is required at the
migration front of melanoma cells [55] and that it has been
shown to colocate with integrin avb3 in melanoma cells [56].
Both these proteins play variousmajor roles in melanoma cell
migration, and our study strongly suggests that they are both
targeted by gastrin.
Migrating cancer cells can be protected against apoptosis
or, more precisely, anoikis, a specific form of apoptosis that
occurs when adherent cells detach themselves from their
substrates. This is well evidenced in glioblastomas [31],
a tumor type in which gastrin plays various major biologic
roles [9,17–21]. Decreasing the levels of migrating cancer
cells can restore a certain level of sensitivity to apoptosis,
and hence to the cytotoxic insults induced by proapoptotic
agents [31]. We therefore wondered whether the gastrin-
induced decrease in HT-144 cell migration could induce an
increased degree of sensitivity of these cells to the pro-
apoptotic insults induced by cytotoxic agents, such as cis-
platin and dacarbazine. In fact, although gastrin significantly
decreased the levels of migration of the HT-144 cells, it did
not increase HT-144 cell sensitivity to apoptosis, a feature
that can at least partly be explained by two different facts,
namely that: 1) HT-144 cells are naturally protected against
apoptosis, at least with respect to the constitutive activation
of Akt and mTOR (whereas p53 is still inducible in these
HT-144 cells; cf. Figure 4D), and 2) gastrin has potent
antiapoptotic effects [22,23,42]. The fact that cisplatin in-
duced cytotoxic effects in these HT-144 cells that appeared
to be protected against apoptosis can, at least in part, be
explained by cisplatin-induced cell death unrelated to apop-
tosis, as already demonstrated in the case of several other
cells types [57,58]. However, this study clearly demonstrates
that adding gastrin to cisplatin or dacarbazine in vitro in
HT-144 cell population induced a greater delay in the devel-
opment of the HT-144 tumor cell population in the scratch
wound assay than was the case with gastrin or the cytotoxic
agent alone. This relates to the combination of both the anti-
migratory effects of gastrin and the cytotoxic effects of cis-
platin or dacarbazine.
We recently showed that gastrin induces potent proangio-
genic effects both in vitro in human umbilical vein endothelial
cells and in vivo in experimental glioblastomas [9]. These
gastrin-induced effects occurred, at least in part, through
modifications to the expression of E-selectin and P-selectin
at the surface of endothelial cells, as well as through asso-
ciations with chemokines, including IL-8 at least [9]. We
therefore wondered whether gastrin could also modify neo-
angiogenesis levels in experimental in vivo humanmelanoma
xenografts. The data in Figure 5 clearly evidence that the
chronic use of a selective antagonist of the CCKB gastrin
receptor (that prevents the biologic effects induced by endo-
genous gastrin) on human C32 melanoma xenografts signif-
icantly decreased the growth levels of these C32 tumors
with a concomitant decrease in neoangiogenesis levels.
These data therefore emphasize the proangiogenic effects
for gastrin in experimental melanomas, as already evidenced
in experimental glioblastomas [9] and pancreatic cancers
(data not shown).
In conclusion, although human melanoma cells seem to
be devoid of conventional CCKA and CCKB/gastrin recep-
tors, in vitro gastrin nevertheless significantly modifies the
migration rates of human melanoma cells at both motility and
invasion levels. These gastrin-mediated modifications ob-
served in the case of melanoma cell migration could be
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mediated by the CCKC receptor. In contrast, gastrin seems
not to induce any modifications to the growth characteristics
of human melanoma cells.
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